Immune system drug trial targets Hard-to-Treat brain cancers
NCT ID NCT03718767
Summary
This study is testing whether the immunotherapy drug nivolumab can help control the growth of certain brain tumors (gliomas) that have specific genetic changes. It is enrolling 62 adults whose tumors have either a very high number of mutations or a normal number. The main goal is to see if the drug can stop the tumors from getting worse for at least six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.